论文部分内容阅读
概述70年代是免疫学的技术革命时代。Koh-ler和Milstein(1975)将冈田(1958)的细胞融合技术应用到免疫球蛋白的生产,从而为医学和生物学的发展开辟了新道路。他们把经绵羊红细胞(SRBC)免疫的小鼠(BALB/C)脾细胞与来自BALB/C小鼠的骨髓瘤细胞(P3-X63-Ag8)一起用仙台病毒处理后获得了融合细胞(即杂交瘤细胞)。这种细胞可持续产生抗SRBC抗体。应用杂交瘤细胞所制备的单克隆抗体较之历来免疫同种
Overview The 1970s were the era of technological revolution in immunology. Koh-ler and Milstein (1975) applied Okada’s (1958) cell fusion technique to immunoglobulin production, opening up new avenues for the development of medicine and biology. They obtained fused cells (ie hybridized with Sendai virus) of mouse (BALB / C) splenocytes immunized with sheep erythrocytes (SRBC) and myeloma cells (P3-X63- Ag8) from BALB / c mice Tumor cells). This cell sustains the production of anti-SRBC antibodies. Monoclonal antibodies prepared using hybridoma cells are more immunologically homogeneous than ever